Colchicine: Nursing Drug Guide, Interaction Toxicity & NCLEX Review

Colchicine is the generic name on most inpatient and outpatient orders. Tablet strengths are commonly 0.6 mg per FDA labeling reviewed for this guide.

Common brands (United States): Colcrys, Mitigare, Gloperba (oral solution). Verify product and indication—dosing regimens differ for gout prophylaxis, gout flare treatment, and familial Mediterranean fever (FMF).

Colchicine has anti-inflammatory effects in gout and is established for long-term use in FMF. It does not lower serum urate—urate-lowering therapy is separate.

↔On a small screen, swipe or scroll sideways to see the full table.

Colchicine is not recommended for pediatric prophylaxis or treatment of gout flares per labeling. Safety and efficacy of repeat flare courses beyond initial treatment have not been fully evaluated.

Colchicine disrupts microtubule polymerization and has multiple effects on leukocyte migration and inflammatory mediators in gout. In FMF it reduces attack frequency. The drug is metabolized in part by CYP3A4 and is a substrate of P-glycoprotein (P-gp)—inhibitors of these pathways raise plasma levels and toxicity risk without changing the ordered tablet dose on the MAR.

Dosing depends on indication, age, renal function, hepatic function, and interacting drugs. Individualize per prescribing information Table 1 and renal/hepatic sections.

Renal and hepatic adjustment highlights

↔On a small screen, swipe or scroll sideways to see the full table.

During prophylaxis, a flare may be treated at doses not exceeding 1.2 mg at first sign followed by 0.6 mg one hour later; wait 12 hours then resume prophylactic dose per labeling.

Pretreatment checks

• Confirm indication (prophylaxis vs flare vs FMF) and that total daily dose does not exceed labeling maximum
• Review creatinine, estimated Clcr/eGFR, and liver function tests when impairment is possible
• Screen for strong CYP3A4 inhibitors (clarithromycin, ketoconazole, ritonavir, etc.), P-gp inhibitors (cyclosporine, ranolazine), moderate inhibitors (diltiazem, erythromycin, grapefruit), and statins (atorvastatin, simvastatin)
• Assess for diarrhea, vomiting, muscle pain, or weakness since last dose
• Verify patient is not consuming grapefruit or grapefruit juice

Contraindications

• Renal or hepatic impairment with P-gp or strong CYP3A4 inhibitors—do not coadminister per labeling
• Known hypersensitivity to colchicine

Important interactions

↔On a small screen, swipe or scroll sideways to see the full table.

Route: Oral tablet (0.6 mg per labeling reviewed).

• Administer with or without food per patient tolerance; GI effects are common
• For gout flare: give 1.2 mg at first sign of flare, then 0.6 mg one hour later—do not exceed 1.8 mg in one hour
• Do not crush or split tablets unless prescriber/pharmacy specifies (e.g., 0.3 mg half-tablet regimens in interaction tables)
• Store securely—fatal accidental ingestion reported in children

• Gout flare: decreased joint pain, warmth, and swelling within 12–24 hours when flare regimen is appropriate
• Prophylaxis: fewer or shorter gout flares during urate-lowering therapy initiation (often first six months)
• FMF: reduced attack frequency and severity over weeks
• Mild transient GI upset may occur at therapeutic doses—escalate if diarrhea becomes severe or persistent

Hold colchicine and escalate immediately when toxicity or interaction risk is suspected—do not administer the next scheduled dose while awaiting review.

• Severe or bloody diarrhea, persistent vomiting, or dehydration after colchicine
• New diffuse muscle weakness, myalgia, or dark urine suggesting rhabdomyolysis—especially with statins
• Rising creatinine, oliguria, or signs of acute kidney injury
• Nausea with bone marrow suppression signs (fever, infection, bleeding, pallor)
• New strong CYP3A4/P-gp inhibitor started without colchicine dose adjustment—especially with renal or hepatic impairment
• Suspected intentional or accidental overdose—contact poison control or medical toxicology per facility protocol and local emergency guidance

↔On a small screen, swipe or scroll sideways to see the full table.

Fatal overdoses have occurred with ingestion as low as 7 mg over four days; severe toxicity and mortality correlate with dose per kg in case series. Early signs include nausea, vomiting, diarrhea, and abdominal pain; later: multi-organ failure, cytopenias, and cardiac effects.

Labeling guidance

• No specific antidote is known
• Treatment: gastric lavage and shock prevention when appropriate; otherwise symptomatic and supportive care
• Colchicine is not effectively removed by dialysis
• Contact poison control or medical toxicology services per facility protocol and local emergency guidance for significant ingestion or suspected interaction toxicity

• Colchicine vs allopurinol—different roles (flare/prophylaxis vs urate lowering); often coprescribed—do not swap or duplicate intent
• Colchicine vs colchicine + inhibitor—same tablet strength on MAR after new antibiotic may now be toxic—reconcile interactions
• 0.6 mg vs 1.2 mg—flare loading uses multiple tablets in one hour; independent double-check high-risk doses
• Home colchicine continuation—patients may self-treat flares above labeling limits; teach maximum flare dose
• Pediatric gout—colchicine not recommended for pediatric gout flare/prophylaxis per labeling—question erroneous orders

↔On a small screen, swipe or scroll sideways to see the full table.

↔On a small screen, swipe or scroll sideways to see the full table.

Monitor

• GI symptoms—diarrhea frequency and severity at each visit
• Creatinine, BUN, eGFR when renal impairment or new interacting drugs
• CK and muscle symptoms when statins or other myotoxic drugs are combined
• CBC if myelosuppression or overdose suspected
• Medication list at every transition—especially new antibiotics and antifungals

Document

• Indication and maximum daily dose verified
• Pharmacy interaction review when inhibitors added
• Hold events with prescriber/pharmacist notification and patient education on grapefruit avoidance
• Flare treatment doses and time of second 0.6 mg dose when applicable

• Do not exceed labeled flare total (1.8 mg in one hour)—more is not more effective and increases toxicity
• Report severe diarrhea, vomiting, muscle pain, weakness, numbness, or unusual bleeding immediately
• Avoid grapefruit and grapefruit juice during treatment
• Tell all clinicians and pharmacists about colchicine before starting new antibiotics or antifungals
• Store tablets securely away from children—fatal accidental ingestion reported
• Do not double prophylaxis doses if one is missed—contact prescriber/pharmacist for guidance

Do not give and contact the prescriber/pharmacist when:

Hold parameters may vary by institutional protocol. Follow prescriber orders, pharmacy guidance, and facility policy.

Rehearse NCLEX-style clinical judgment practice for colchicine CYP3A4/P-gp interaction toxicity using a tabbed inpatient case (MAR, labs, history, nursing notes), then priority action, cue recognition (SATA), post-hold trend interpretation (SATA), matrix urgency, interaction MCQ, and flare-dose cloze—recognise cues → analyse → prioritise → act → evaluate outcomes.

This medication guide is written and reviewed using NurseOnShift editorial and clinical review standards.

• Editorial Policy
• Medical Review Process
• Disclaimer

Educational use only. This content does not replace clinical judgment, prescriber orders, pharmacist guidance, product labeling, or institutional protocols.